Jul 9, 2026 · 5 min

Micron bets big on US chipmaking as drug trial rattles AstraZeneca

Micron Rises, AstraZeneca Dives, Meta Falls on Report AI Chip Heading to Production On this episode of Stock Movers:

The market moves reflect competing pressures on technology and healthcare companies: industrial investment and AI expectations on one side, clinical failure on the other.

3 key takeaways

1Micron plans to invest $250 billion in US plants to expand domestic memory chip production.
2AstraZeneca shares fell after a late-stage trial for a new heart drug failed.
3Meta declined amid reports about its upcoming AI chip production timeline and developer pricing.

Don't miss

Micron’s planned $250 billion investment in US plants stands out as the episode’s largest and most concrete market-moving development.

The brief

Bloomberg Radio’s Stock Movers roundup follows three sharply different catalysts: Micron’s US manufacturing plans, AstraZeneca’s failed heart-drug trial, and Meta’s AI-chip timeline.

Micron’s stock rose as the company outlined plans to invest $250 billion in US plants, linking a major market move to expanded domestic memory-chip production.

AstraZeneca moved in the opposite direction after a late-stage trial for a new heart drug failed, showing how clinical results can quickly reshape a pharmaceutical company’s outlook.

Meta also fell amid reports about when its upcoming AI chip will enter production, alongside discussion of developer pricing and the uncertainty surrounding its hardware strategy.

Together, the moves show three distinct ways expectations change stock prices: factory investment, medical evidence, and the timing of an AI product rollout.

What was said on this episode

4 statements · 2 positive · 2 neutral

Juni Legruon Micron U.S. plant spendingPositive1:05
Micron is raising planned U.S. plant spending to $250 billion.
“the company announced today that it is raising its planned spending on new plants in the US to $250 billion”
Listen at 1:05
Juni Legruon Meta model access pricingNeutral2:49
Meta is beginning to charge developers for access to its models.
“Meta is starting to charge developers for access to its models”
Listen at 2:49
Juni Legruon Meta developer pricingPositive2:53
Mark Zuckerberg characterized Meta’s developer pricing as aggressive and attractive.
“Mark Zuckerberg called this pricing very quote, aggressive and attractive”
Listen at 2:53
Juni Legruon Meta AI-chip production collaborationNeutral3:13
Meta is collaborating with Broadcom, TSMC, and Samsung on AI-chip production.
“Meta is working with Broadcom to design TSMC to manufacture and it has some long term agreements with Samsung for memory chips SanDisk”
Listen at 3:13

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Mentioned

MTMicron Technology AAstraZeneca